JP2007519739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007519739A5 JP2007519739A5 JP2006551478A JP2006551478A JP2007519739A5 JP 2007519739 A5 JP2007519739 A5 JP 2007519739A5 JP 2006551478 A JP2006551478 A JP 2006551478A JP 2006551478 A JP2006551478 A JP 2006551478A JP 2007519739 A5 JP2007519739 A5 JP 2007519739A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- diabetes
- antibody
- treatment
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 206010012601 diabetes mellitus Diseases 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 239000004615 ingredient Substances 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 239000004480 active ingredient Substances 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 229940122199 Insulin secretagogue Drugs 0.000 claims 5
- 229940122355 Insulin sensitizer Drugs 0.000 claims 5
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 5
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 5
- 229940100389 Sulfonylurea Drugs 0.000 claims 5
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 5
- 230000003579 anti-obesity Effects 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 230000002440 hepatic effect Effects 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 239000003613 bile acid Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 claims 4
- 239000008177 pharmaceutical agent Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 230000000580 secretagogue effect Effects 0.000 claims 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 3
- 206010056997 Impaired fasting glucose Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 3
- 201000008980 hyperinsulinism Diseases 0.000 claims 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 2
- 229940125753 fibrate Drugs 0.000 claims 2
- 208000004104 gestational diabetes Diseases 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000001589 microsome Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 230000008506 pathogenesis Effects 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002461 renin inhibitor Substances 0.000 claims 2
- 229940086526 renin-inhibitors Drugs 0.000 claims 2
- 239000003352 sequestering agent Substances 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 229940124681 11 beta HSD inhibitor Drugs 0.000 claims 1
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 1
- 229940097420 Diuretic Drugs 0.000 claims 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 claims 1
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940122344 Peptidase inhibitor Drugs 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 230000023852 carbohydrate metabolic process Effects 0.000 claims 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 230000019439 energy homeostasis Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53955004P | 2004-01-27 | 2004-01-27 | |
| US56649904P | 2004-04-29 | 2004-04-29 | |
| PCT/US2005/002609 WO2005072385A2 (en) | 2004-01-27 | 2005-01-27 | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007519739A JP2007519739A (ja) | 2007-07-19 |
| JP2007519739A5 true JP2007519739A5 (enExample) | 2008-05-01 |
Family
ID=34830483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551478A Pending JP2007519739A (ja) | 2004-01-27 | 2005-01-27 | 下垂体細胞アデニル酸シクラーゼ活性化ペプチド（ｐａｃａｐ）受容体（ｖｃａｐ２）アゴニストおよびそれらの製薬学的使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090143283A1 (enExample) |
| EP (1) | EP1713493A4 (enExample) |
| JP (1) | JP2007519739A (enExample) |
| KR (1) | KR20070009554A (enExample) |
| AU (1) | AU2005208911A1 (enExample) |
| BR (1) | BRPI0507177A (enExample) |
| CA (1) | CA2554475A1 (enExample) |
| EC (1) | ECSP066793A (enExample) |
| IL (1) | IL176705A0 (enExample) |
| MA (1) | MA28335A1 (enExample) |
| NO (1) | NO20063801L (enExample) |
| RU (1) | RU2006130691A (enExample) |
| WO (1) | WO2005072385A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101001639A (zh) * | 2004-06-12 | 2007-07-18 | 拜尔药品公司 | 血管活性肠肽(vip)/垂体腺苷酸环化酶活化肽(pacap)受体2(vpac2)激动剂的聚乙二醇化和使用方法 |
| EP1896048A4 (en) * | 2005-05-06 | 2010-11-03 | Bayer Pharmaceuticals Corp | PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE |
| JP2009519212A (ja) * | 2005-10-26 | 2009-05-14 | イーライ リリー アンド カンパニー | 選択的ｖｐａｃ２受容体ペプチドアゴニスト |
| US9782454B2 (en) | 2010-04-22 | 2017-10-10 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| US9789164B2 (en) | 2013-03-15 | 2017-10-17 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
| WO2016168757A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
| JP7116685B2 (ja) | 2016-04-15 | 2022-08-10 | エイチ． ルンドベック アー／エス | ヒト化抗ｐａｃａｐ抗体及びそれらの使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU656230B2 (en) * | 1991-10-11 | 1995-01-27 | F. Hoffmann-La Roche Ag | Cyclic vasoactive peptides |
| CA2379604A1 (en) * | 1999-09-28 | 2001-04-05 | Bayer Corporation | Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use |
| WO2003068805A2 (en) * | 2002-02-14 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Formulation strategies in stabilizing peptides in organic solvents and in dried states |
| BR0312621A (pt) * | 2002-07-12 | 2005-12-06 | Bayer Pharmaceuticals Corp | Agonistas de receptor (vpac2) de peptìdeo de ativação de pituitária adenilato ciclase (pacap) |
-
2005
- 2005-01-27 WO PCT/US2005/002609 patent/WO2005072385A2/en not_active Ceased
- 2005-01-27 AU AU2005208911A patent/AU2005208911A1/en not_active Abandoned
- 2005-01-27 KR KR1020067015124A patent/KR20070009554A/ko not_active Withdrawn
- 2005-01-27 BR BRPI0507177-1A patent/BRPI0507177A/pt not_active IP Right Cessation
- 2005-01-27 RU RU2006130691/15A patent/RU2006130691A/ru not_active Application Discontinuation
- 2005-01-27 CA CA002554475A patent/CA2554475A1/en not_active Abandoned
- 2005-01-27 JP JP2006551478A patent/JP2007519739A/ja active Pending
- 2005-01-27 US US10/586,124 patent/US20090143283A1/en not_active Abandoned
- 2005-01-27 EP EP05712166A patent/EP1713493A4/en not_active Withdrawn
-
2006
- 2006-07-04 IL IL176705A patent/IL176705A0/en unknown
- 2006-07-24 MA MA29206A patent/MA28335A1/fr unknown
- 2006-08-25 NO NO20063801A patent/NO20063801L/no not_active Application Discontinuation
- 2006-08-25 EC EC2006006793A patent/ECSP066793A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6759373B2 (ja) | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 | |
| Baetta et al. | Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences | |
| US10603283B2 (en) | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| TWI432200B (zh) | 二肽基肽酶抑制劑之投予 | |
| Gallwitz | Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | |
| KR101438234B1 (ko) | 의약의 병용 및 그 용도 | |
| KR101894228B1 (ko) | 리나글립틴 및 임의로 ｓｇｌｔ２ 억제제를 포함하는 약제학적 조성물 및 이의 용도 | |
| KR102062824B1 (ko) | 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도 | |
| RU2600440C2 (ru) | Твердые композиции, содержащие агонист glp-1 и соль n-(2-гидроксибензоил)амино)каприловой кислоты | |
| Gerich | DPP-4 inhibitors: what may be the clinical differentiators? | |
| TWI609702B (zh) | 層狀醫藥調配物 | |
| Graefe-Mody et al. | Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects | |
| JP2006506969A5 (enExample) | ||
| Kim et al. | Pharmaceutical application and development of fixed-dose combination: Dosage form review | |
| KR20130123467A (ko) | Ｇｌｐ-1에 의한 유해 효과의 예방 방법 | |
| KR20200013100A (ko) | 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료 | |
| KR20110040883A (ko) | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 | |
| KR20110115582A (ko) | Ｄｐｐ－４ 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제 | |
| JP2003530342A (ja) | ＡＴ１レセプターアンタゴニスト又はＡＣＥインヒビター又はＨＭＧ−Ｃｏ−Ａレダクターゼインヒビターからなる群から選ばれた少なくとも２つの化合物の組合せ | |
| Lau et al. | Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function | |
| KR20190017936A (ko) | 리나글립틴 및 메트포르민의 병용물 | |
| JP2007519739A5 (enExample) | ||
| KR20170123704A (ko) | 제2형 당뇨병 환자의 치료 | |
| Goebel et al. | Effective treatment of hypertension by AT1 receptor antagonism: the past and future of telmisartan | |
| RU2006130691A (ru) | Агонисты рецептора (vpac2), активирующего аденилатциклазу гипофиза пептида (расар), и фармакологические способы их применения |